Nektar Therapeutics (NKTR) Asset Writedowns and Impairment (2012 - 2025)

Nektar Therapeutics' Asset Writedowns and Impairment history runs 5 years deep, the most recent figure standing at $4.4 million for Q4 2025.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $4.4 million in Q4 2025; TTM through Dec 2025 was $4.4 million, a 46.68% decrease from a year earlier, with the FY2025 full-year figure at $4.4 million, down 46.68% from the prior year.
• Asset Writedowns and Impairment fell to $4.4 million in Q4 2025 per NKTR's latest filing, from $8.3 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $57.3 million in Q2 2022 and bottomed at -$1000.0 in Q4 2023.
• The 4-year median for Asset Writedowns and Impairment is $7.2 million (2022), against an average of $11.9 million.
• Biggest YoY gain for Asset Writedowns and Impairment was 747.75% in 2023; the steepest drop was 100.01% in 2023.
• Year by year, Asset Writedowns and Impairment stood at $7.2 million in 2022, then slumped by 100.01% to -$1000.0 in 2023, then jumped by 833000.0% to $8.3 million in 2024, then tumbled by 46.68% to $4.4 million in 2025.
• Per Business Quant, the three latest NKTR Asset Writedowns and Impairment figures stand at $4.4 million (Q4 2025), $8.3 million (Q2 2024), and -$1000.0 (Q4 2023).